Intradermal delivery of imiquimod using polymeric microneedles for basal cell carcinoma

Sabri, Akmal Hidayat Bin; Cater, Zachary; Gurnani, Pratik; Ogilvie, Jane; Segal, Joel; Scurr, David J.; Marlow, Maria

doi:10.1016/j.ijpharm.2020.119808

Cited by 35 publications

(28 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doing so enables the ease of demolding without fracturing the microneedle tips. 32 In addition, the use of surfactants in the manufacture of microneedles has been widely explored in the manufacture of coated microneedles. 33 − 37 In this instance, surfactants help to reduce the surface tension of coating solutions to ensure improved and consistent wetting of the microneedle surface.…”

Section: Introductionmentioning

confidence: 99%

Elucidating the Impact of Surfactants on the Performance of Dissolving Microneedle Array Patches

et al. 2022

View full text Add to dashboard Cite

The need for biocompatible polymers capable of dissolving in the skin while exhibiting reasonable mechanical features and delivery efficiency limits the range of materials that could be utilized in fabricating dissolving microneedle array patches (MAPs). The incorporation of additives, such as surfactants, during microneedle fabrication might be an alternative solution to overcome the limited range of materials used in fabricating dissolving MAPs. However, there is a lacuna in the knowledge on the effect of surfactants on the manufacture and performance of dissolving MAPs. The current study explores the role of surfactants in the manufacture and performance of dissolving MAPs fabricated from poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP) loaded with the model drugs, ibuprofen sodium and itraconazole. Three nonionic surfactants, Lutrol F108, Pluronic F88, and Tween 80, in solutions at varying concentrations (0.5, 1.0, and 2.0% w/w) were loaded into these dissolving MAPs. It was discovered that all of the dissolving MAPs that incorporated surfactant displayed a lower reduction in the microneedle height (≈10%) relative to the control formulation (≈20%) when subjected to a compressive force of 32 N. In addition, the incorporation of surfactants in some instances enhanced the insertion profile of these polymeric MAPs when evaluated using ex vivo neonatal porcine skin. The incorporation of surfactant into ibuprofen sodium-loaded dissolving MAPs improved the insertion depth of MAPs from 400 μm down to 600 μm. However, such enhancement was not apparent when the MAPs were loaded with the model hydrophobic drug, itraconazole. Skin deposition studies highlighted that the incorporation of surfactant enhanced the delivery efficiency of both model drugs, ibuprofen sodium and itraconazole. The incorporation of surfactant enhanced the amount of ibuprofen sodium delivered from 60.61% up to ≈75% with a majority of the drug being delivered across the skin and into the receptor compartment. On the other hand, when surfactants were added into MAPs loaded with the model hydrophobic drug itraconazole, we observed enhancement in intradermal delivery efficiency from 20% up to 30%, although this did not improve the delivery of the drug across the skin. This work highlights that the addition of nonionic surfactant is an alternative formulation strategy worth exploring to improve the performance and delivery efficiency of dissolving MAPs.

show abstract

Section: Introductionmentioning

confidence: 99%

Elucidating the Impact of Surfactants on the Performance of Dissolving Microneedle Array Patches

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, skin cross sections showed intradermal co-localization of the PVPVA polymer, with imiquimod within the MN channels, illustrating it a viable approach for efficient delivery of imiquimod for nodular BCC. [156] PLGA NPs Peptide P20 (CSSRTMHHC) and combined peptide C. Combined peptide C comprised of a tumor-homing peptide “C” (CVNHPAFAC), conjugated to (HTMYYHHYQHHL) an antiangiogenic peptide with a GYG. 800–100 nm Poly(lactide-co-glycolide) acid (PLGA), is a biodegradable copolymer approved by FDA for use in humans.…”

Section: Polymer-based Structures: Management Of Skin Cancermentioning

confidence: 99%

Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures

Khan

Mir

Qian

et al. 2022

Journal of Advanced Research

101

View full text Add to dashboard Cite

show abstract

“…Researches can also combine the mechanical power of two or more polymers and additional materials [ 45 ]. Furthermore, during polymer selection, the target tissue for the MN must be called transdermal or non-transdermal [ 46 , 47 ]. Aimed at soft tissues that cannot withstand pressure from the high-strength MN implant, careful balancing of strength and versatility must be considered [ 48 ].…”

Section: Materials Choice and Drug Release Kinetics Of Polymeric Microneedlesmentioning

confidence: 99%

“…Animal Models. Most pharmacological studies are conducted through in vivo animal models [ 46 , 50 , 220 , 221 , 222 , 223 ]. The animal fur was removed from the anesthetized animal, and the MN patch was subsequently applied to the underlying skin.…”

Section: Pharmacokinetic and Drug Release Behavior From Polymeric Mnsmentioning

confidence: 99%

“…Therapeutic techniques to treat BCC such as curettage, cautery, cryotherapy [ 253 ] exist, including the topical use of creams such as imiquimod (IMQ) and 5-fluorouracil (5-FU) as a noninvasive approach [ 254 ]. MNs have been introduced to improve the skin’s permeability of molecules as delivery efficiency is not optimized by the sole use of such creams [ 46 ]. Most of the drug remains in the formulation and is not delivered [ 255 ].…”

Section: Key Human Diseases Studied By Polymeric Mnsmentioning

confidence: 99%

See 1 more Smart Citation

Translation of Polymeric Microneedles for Treatment of Human Diseases: Recent Trends, Progress, and Challenges

Yadav

Munni²,

Campbell

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

The ongoing search for biodegradable and biocompatible microneedles (MNs) that are strong enough to penetrate skin barriers, easy to prepare, and can be translated for clinical use continues. As such, this review paper is focused upon discussing the key points (e.g., choice polymeric MNs) for the translation of MNs from laboratory to clinical practice. The review reveals that polymers are most appropriately used for dissolvable and swellable MNs due to their wide range of tunable properties and that natural polymers are an ideal material choice as they structurally mimic native cellular environments. It has also been concluded that natural and synthetic polymer combinations are useful as polymers usually lack mechanical strength, stability, or other desired properties for the fabrication and insertion of MNs. This review evaluates fabrication methods and materials choice, disease and health conditions, clinical challenges, and the future of MNs in public healthcare services, focusing on literature from the last decade.

show abstract

Intradermal delivery of imiquimod using polymeric microneedles for basal cell carcinoma

Cited by 35 publications

References 78 publications

Elucidating the Impact of Surfactants on the Performance of Dissolving Microneedle Array Patches

Elucidating the Impact of Surfactants on the Performance of Dissolving Microneedle Array Patches

Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures

Translation of Polymeric Microneedles for Treatment of Human Diseases: Recent Trends, Progress, and Challenges

Contact Info

Product

Resources

About